Clinical Trials
3 trialsNCT00788775 2018-11-15
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01028222 2015-12-30
TEAM
Novartis
Phase 2 Completed
NCT01168050 2011-02-08
NILOMEL
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown